Dr. med. Helmut Pabst, c/o Sportschule Puch
- Address
- Am Fuchsbogen 9, 82556 Fürstenfeldbruck, Germany
Dr. med. Helmut Pabst - Sports Medicine Research Center
Dr. med. Helmut Pabst's research center, located at Sportschule Puch, specializes in clinical investigations of sports-related injuries and their treatment modalities. The center focuses on acute musculoskeletal injuries commonly encountered in athletic populations, with particular expertise in evaluating topical pharmaceutical interventions for rapid symptom relief.
- Acute ankle sprains and ligamentous injuries
- Topical analgesic and anti-inflammatory therapies
- Pain management in sports medicine
The center conducts rigorous randomized controlled trials to assess the efficacy and safety of novel treatment approaches for acute ankle sprains. Their research methodology emphasizes validated pain assessment tools, including Visual Analogue Scale (VAS) measurements for pain-on-movement, providing objective data on short-term therapeutic outcomes. This sports medicine-focused facility is uniquely positioned to evaluate interventions that enable rapid return to activity while ensuring optimal healing of grade I ankle injuries.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Teikoku Seiyaku Co. Ltd.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Dr. med. Helmut Pabst, c/o Sportschule Puch
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Comparison of Herbal Medicinal Products in Acute Bronchitis: Liquid Extract from Thyme Herb, Primrose Root Tincture, and Ivy Leaf Extract | Engelhard Arzneimittel GmbH & Co. KG | Phase III | Not Recruiting | Feb 2024 | Apr 2024 |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Esflurbiprofen | 2 | Unknown | 2025-02-12 | 2025-03-06 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.